首页|多西他赛联合PD-1抑制剂对晚期非小细胞肺癌预后及血清MMP-9、TIMP-1水平的影响

多西他赛联合PD-1抑制剂对晚期非小细胞肺癌预后及血清MMP-9、TIMP-1水平的影响

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
目的 探讨多西他赛联合程序性死亡受体1(PD-1)抑制剂对晚期非小细胞肺癌(NSCLC)预后及血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制剂-1(TIMP-1)水平的影响.方法 将90例晚期NSCLC患者随机分为研究组和对照组,每组45例.对照组给予多西他赛和顺铂治疗,研究组在对照组治疗基础上给予PD-1治疗,3周为1个治疗周期,共治疗6个周期.比较2组治疗后客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS),观察2组治疗期间不良反应发生情况及治疗前后血清MMP-9、TIMP-1水平的变化.结果 研究组治疗后DCR、PFS、OS显著高于对照组(P＜0.05);治疗期间2组不良反应发生率比较差异无统计学意义(P＞0.05);2组治疗后血清MMP-9、TIMP-1水平较治疗前显著降低(P＜0.05),且研究组降低较对照组更为显著(P＜0.05).结论 多西他赛联合PD-1抑制剂对晚期NSCLC具有较好的疗效和预后,能够降低血清MMP-9、TIMP-1水平,降低肺癌细胞侵袭转移的能力,安全性良好.
Clinical Efficacy of Docetaxel Combined with PD-1 Inhibitor on the Prognosis and MMP-9 and TIMP-1 in Advanced Non-small Cell Lung Cancer
Objective To investigate the effects of docetaxel combined with programmed death receptor 1(PD-1)inhibitor on the prognosis and the levels of serum matrix metalloproteinase 9(MMP-9)as well as tissue inhibitor of matrix metalloproteinase 1(TIMP-1)in advanced non-small cell lung cancer(NSCLC).Methods 90 patients with advanced NSCLC were randomly di-vided into the study group and the control group,45 cases in each group.The control group was given docetaxel and cisplatin treatment,and the study group was further given PD-1 treatment,with 3 weeks as 1 treatment cycle and a total of 6 cycles of treatment.Objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),and overall survival(OS)were compared between the 2 groups,and the occurrence of adverse reactions during the treat-ment period and the changes of serum MMP-9 and TIMP-1 levels before and after the treatment were observed in the 2 groups.Results The DCR,PFS and OS of the study group were signifi-cantly higher than those of the control group after treatment(P＜0.05);the difference in the inci-dence of adverse reactions between the 2 groups during the treatment period was not statistically significant(P＞0.05);the levels of serum MMP-9 and TIMP-1 in the 2 groups after treatment were significantly reduced compared with those before treatment(P＜0.05),and the reduction in the study group was more significant than that in the control group(P＜0.05).Conclusion Do-cetaxel combined with PD-1 inhibitor might have better clinical efficacy and prognosis in advanced NSCLC.It can reduce serum MMP-9 and TIMP-1 levels,and attenuate the invasion and metastasis ability of lung cancer cells,with good safety profile.

docetaxelprogrammed death receptor 1 inhibitoradvanced non-small cell lung cancerserum matrix metalloproteinase 9tissue inhibitor of matrix metalloproteinase 1clinical efficacy

吴仁瑞、钟琼、黄蓉

展开 >

赣州市人民医院肿瘤科,江西赣州 341000

多西他赛 PD-1抑制剂 晚期非小细胞肺癌 基质金属蛋白酶9 基质金属蛋白酶组织抑制剂1 临床疗效

赣州市指导性科技计划

GZ2018ZSF304

2024

10.13764/j.cnki.lcsy.2024.02.003

实用临床医学
南昌大学

实用临床医学

影响因子：0.818
ISSN：1009-8194
年,卷(期)：2024.25(2)
  • 22